Cellectis SA (NASDAQ:CLLS)’s share price traded down 9.6% during mid-day trading on Friday . The stock traded as low as $23.95 and last traded at $24.16, with a volume of 281,943 shares trading hands. The stock had previously closed at $26.72.

Several equities analysts recently issued reports on the stock. Ladenburg Thalmann assumed coverage on shares of Cellectis SA in a research report on Tuesday, April 5th. They set a “buy” rating and a $45.00 price target on the stock. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Cellectis SA in a report on Monday, June 20th. Zacks Investment Research cut shares of Cellectis SA from a “buy” rating to a “hold” rating in a report on Thursday, March 17th. Finally, Piper Jaffray Cos. restated a “buy” rating on shares of Cellectis SA in a report on Wednesday, March 16th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $44.67.

The stock’s market cap is $885.98 million. The stock has a 50-day moving average of $29.19 and a 200 day moving average of $26.94.

Cellectis SA (NASDAQ:CLLS) last released its earnings results on Thursday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.18. Analysts forecast that Cellectis SA will post ($2.07) EPS for the current year.

A hedge fund recently raised its stake in Cellectis SA stock. Tekla Capital Management LLC boosted its stake in Cellectis SA (NASDAQ:CLLS) by 30.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 207,250 shares of the company’s stock after buying an additional 48,868 shares during the period. Tekla Capital Management LLC owned 0.59% of Cellectis SA worth $6,431,000 as of its most recent filing with the SEC.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.